Robert D Moore1, James C Lukban. 1. Atlanta Urogynecology Associates, 3400-C Old Milton Parkway, Suite 330, Atlanta, GA, USA. moorer33@hotmail.com
Abstract
INTRODUCTION AND HYPOTHESIS: The objective of the study was to compare extrusion (vaginal mesh exposure) rates in patients undergoing transvaginal prolapse repair with the trocar-based Apogee and/or Perigee devices (American Medical Systems, Minnetonka, MN, USA) using either the original type I polypropylene mesh (IntePro, American Medical Systems, Minnetonka, MN, USA) or a newer generation lightweight type I mesh (IntePro Lite, American Medical Systems, Minnetonka, MN, USA). METHODS: Data were pooled from three similarly designed prospective multicenter studies evaluating the safety and efficacy of Perigee for correction of the anterior (AC) and/or Apogee to repair the posterior/apical (PC/A) compartments. The first two studies utilized IntePro (mesh density 50 g/m(2)) and the third utilized IntePro Lite (mesh density 25.2 g/m(2)). Data were pooled to form IntePro and IntePro Lite groups for comparison. Patient demographics were recorded. Risk factors for vaginal mesh exposure were also considered. RESULTS: Two hundred and sixty-three patients were implanted with Perigee and/or Apogee with IntePro for a total of 371 heavier mesh implants (174 Perigee, 197 Apogee) compared to 86 patients who underwent Perigee and/or Apogee with IntePro Lite for a total of 116 lightweight mesh implants (60 Perigee, 56 Apogee). Demographics and potential risk factors for extrusion were compared between the two groups. Mean follow-up was 2.0 years and similar between the two groups. In the AC, there were 234 implants, with mesh extrusion occurring in 8.0 % following IntePro compared to 5.0 % following IntePro Lite (p = 0.57). In the PA/C, there were 253 implants, with mesh extrusion occurring in 13.7 % following IntePro compared to 7.1 % following IntePro Lite (p = 0.25). Overall mesh extrusion rates in 487 implants in all compartments were found to be 11.1 % with IntePro versus 6.0 % with IntePro Lite with an estimated odds ratio of 1.93 (95 % confidence interval 0.84-4.44, p = 0.12). CONCLUSIONS: No statistically significant difference in extrusion rates were seen following use of IntePro versus IntePro Lite; however, the 46 % reduction in rate of mesh exposure observed in those receiving the lighter weight mesh may represent clinical importance.
INTRODUCTION AND HYPOTHESIS: The objective of the study was to compare extrusion (vaginal mesh exposure) rates in patients undergoing transvaginal prolapse repair with the trocar-based Apogee and/or Perigee devices (American Medical Systems, Minnetonka, MN, USA) using either the original type I polypropylene mesh (IntePro, American Medical Systems, Minnetonka, MN, USA) or a newer generation lightweight type I mesh (IntePro Lite, American Medical Systems, Minnetonka, MN, USA). METHODS: Data were pooled from three similarly designed prospective multicenter studies evaluating the safety and efficacy of Perigee for correction of the anterior (AC) and/or Apogee to repair the posterior/apical (PC/A) compartments. The first two studies utilized IntePro (mesh density 50 g/m(2)) and the third utilized IntePro Lite (mesh density 25.2 g/m(2)). Data were pooled to form IntePro and IntePro Lite groups for comparison. Patient demographics were recorded. Risk factors for vaginal mesh exposure were also considered. RESULTS: Two hundred and sixty-three patients were implanted with Perigee and/or Apogee with IntePro for a total of 371 heavier mesh implants (174 Perigee, 197 Apogee) compared to 86 patients who underwent Perigee and/or Apogee with IntePro Lite for a total of 116 lightweight mesh implants (60 Perigee, 56 Apogee). Demographics and potential risk factors for extrusion were compared between the two groups. Mean follow-up was 2.0 years and similar between the two groups. In the AC, there were 234 implants, with mesh extrusion occurring in 8.0 % following IntePro compared to 5.0 % following IntePro Lite (p = 0.57). In the PA/C, there were 253 implants, with mesh extrusion occurring in 13.7 % following IntePro compared to 7.1 % following IntePro Lite (p = 0.25). Overall mesh extrusion rates in 487 implants in all compartments were found to be 11.1 % with IntePro versus 6.0 % with IntePro Lite with an estimated odds ratio of 1.93 (95 % confidence interval 0.84-4.44, p = 0.12). CONCLUSIONS: No statistically significant difference in extrusion rates were seen following use of IntePro versus IntePro Lite; however, the 46 % reduction in rate of mesh exposure observed in those receiving the lighter weight mesh may represent clinical importance.
Authors: Beri Ridgeway; Mark D Walters; Marie Fidela R Paraiso; Matthew D Barber; Sarah E McAchran; Howard B Goldman; J Eric Jelovsek Journal: Am J Obstet Gynecol Date: 2008-10-09 Impact factor: 8.661
Authors: Cheryl B Iglesia; Andrew I Sokol; Eric R Sokol; Bela I Kudish; Robert E Gutman; Joanna L Peterson; Susan Shott Journal: Obstet Gynecol Date: 2010-08 Impact factor: 7.661
Authors: Jacobus W A Burger; Roland W Luijendijk; Wim C J Hop; Jens A Halm; Emiel G G Verdaasdonk; Johannes Jeekel Journal: Ann Surg Date: 2004-10 Impact factor: 12.969
Authors: Reijo Hiltunen; Kari Nieminen; Teuvo Takala; Eila Heiskanen; Mauri Merikari; Kirsti Niemi; Pentti K Heinonen Journal: Obstet Gynecol Date: 2007-08 Impact factor: 7.661
Authors: Rebecca U Margulies; Christina Lewicky-Gaupp; Dee E Fenner; Edward J McGuire; J Quentin Clemens; John O L Delancey Journal: Am J Obstet Gynecol Date: 2008-10-09 Impact factor: 8.661
Authors: J Farthmann; D Watermann; A Niesel; C Fünfgeld; A Kraus; F Lenz; H J Augenstein; E Graf; B Gabriel Journal: Int Urogynecol J Date: 2012-08-29 Impact factor: 2.894
Authors: Adrian Kohut; Taylor Whitaker; Logan Walter; Susan Y Li; Elinor Han; Stephen Lee; Mark T Wakabayashi; Thanh H Dellinger; Ernest S Han; Lorna Rodriguez-Rodriguez; Christopher Chung Journal: Int Urogynecol J Date: 2022-05-02 Impact factor: 2.894
Authors: Dimitri Barski; Holger Gerullis; Evangelos Georgas; Andreas Bär; Bernhard Lammers; Albert Ramon; Dirk Ysebaert; Bernd Klosterhalfen; Mihaly Boros; Thomas Otto Journal: Biomed Res Int Date: 2014-09-16 Impact factor: 3.411